Presented at #ASCO24: Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: nej.md/3wSo3uk

LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 Lecia Sequist, MD, MPH

Great recap of the data with carboplatin for TNBC by Javier Cortes MD PhD #ASCO24

How to treat Early stage rectal cancer ? Useful for clinical decisions. @asco #asco24 OncoAlert LARVOL

All first line metastatic cervical cancer trials in one slide . Money 💰 slide . ESMO - Eur. Oncology #esmogynae24 Oncology Brothers

The future evolution of molecular therapy for endometrial cancer . ESMO - Eur. Oncology #esmogynae24

El GECP elabora la primera guía que estandariza las estrategias terapéuticas en cáncer de ... - goo.gl/alerts/DU8W2g #GoogleAlerts

ESMO GI 2024 take-home messages: Colorectal cancer #ESMOGI24 👉more options: Liver transplantation (TRANSMET), ICI combos (Nivo/Ipi; Botensilimab/Basiliximab..), sequential therapy, molecular selection... ESMO - Eur. Oncology #ESMOAmbassadors

PRODIGE 23: Long-term results Neoadj FOLFIRINOX vs SoC (CRT) 7y-DFS➡️67.6 vs 62.5%✅️ 7y-MFS➡️79.2 vs 72.3%✅️ 7y-OS➡️81.9 vs76.1%✅️✅️ 💥Induction chemotherapy with mFOLFIRINOX improves OS in LARC patients OncoAlert annalsofoncology.org/article/S0923-…

Tom Powles presents #NIAGARA trial - first in #bladdercancer to show IO benefit for neoadjuvant durvalumab-chemo -- improved event free survival and overall survival. Concurrent NEJM publication today! nejm.org/doi/abs/10.105… ESMO - Eur. Oncology OncoAlert #ESMO24 #ESMOAmbassadors

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 NEJM

Hoy es el Día Mundial del Cáncer Ginecológico 💙 Un día en el que queremos recordar a todas nuestras pacientes y aumentar la visibilidad y concienciación. Desde GEICO, seguiremos comprometidos con su investigación. #DíaMundialdelCáncerGinecológico #InvestigaciónOncológica

Comenzando #SEOM24

🔬 El estudio fase III ARIAN en adyuvancia post neoadyuvancia ha comenzado la inclusión de pacientes. 🏥 35 centros y 129 pacientes participarán en esta investigación del GECP. El primer paciente ha sido incluido por el Hospital Universitario de Gran Canaria Doctor Negrín. Un

Lung cancer screening works. 🔘Low Dose CT caught 97% of cancers—most in early stages. 🔘77% had surgery. 1-year false-positive rate? Just 4.8%. This isn’t just data—it’s time saved. Lives extended. #LungCancer #Oncology #EarlyDetection #PublicHealth The Lancet Oncology OncoAlert

🫁‼️ Nuevo estudio del GECP en The Lancet Regional Health – Europe: ⭕Se analiza por 1ª vez en España el riesgo de segundos tumores en supervivientes de #cancerdepulmon según el tratamiento recibido. Abrimos hilo👇 thelancet.com/journals/lanep… M.Provencio

🗣️ Inmunoterapia = 53 % menos riesgo de SPC 🗣️Terapias dirigidas = 30 % menos 🤔El tabaco sigue siendo clave: 👉Fumadores = hasta 60 % más de riesgo

For those interested in reading the full manuscript, here’s a Free Access Link: secure-web.cisco.com/1J1Rutx7mwUbs2…

Hello! 👋 This year, Spanish translations of our uro-oncology flowcharts were created as learning materials for the CONTIGO course in Spain. They are freely available on our website for Spanish-speaking doctors. 🙂👇 knro.link/7dtvvn5q

FOLFOXIRI/bev vs doublets/bev in liver-only/right-sided & RAS/BRAF-mut mCRC 🧬 🔗 ejcancer.com/article/S0959-… 📈 PFS 12.3 vs 10.3m (HR0.75,p=0.019) | ORR 64% vs 53% ⚠️ G3–4 neutropenia 44% vs 22% | 💩 diarrhea 19% vs 4% 🔪 R0 27% vs 24% ✅ Benefit independent of surgery